TABLE 4.

Treatment for chronic hepatitis C virus (HCV) infection among 14 current and former injection drug users initiating therapy at the Street Health Centre in Kingston, Ontario

Patient	Sex	Age, years	HCV genotype			During treatment		Ribavirin compliance, %	Status	Outcome
				Treatment, weeks		Self-reported use of illicit drugs*	Positive tox screen for illicit drugs
				Prescribed	Completed
1	F	39	1	48	48	Yes	Yes	98.2	Completed	SVR
2	M	54	1	48	48	No	No	100	Completed	SVR
3	M	49	3	24	20	Yes	No	97.1	Stopped early due to relapse	N/A
4	M	53	2/3	24	24	No	Yes	100	Completed	SVR
5	F	25	3	24	22	No	Yes	99	Completed	SVR
6	M	49	1	48	48	Yes	Yes	91	Completed	ETR
7	F	48	1	48	10	No	No	97.4	Stopped early due to critical illness and psychosis	N/A
8	F	29	3	24	24	No	No	97	Completed	SVR
9	F	31	1	48	48	Yes	Yes	81	Completed	SVR
10	M	48	1	48	48	No	No	100	Completed	ETR
11	M	56	1	48	19	No	No	100	Stopped early due to illness	ETR
12	F	48	1	48	48	Yes	Yes	99.8	Completed	SVR
13	F	41	1	48	39	Yes	Yes	100	Stopped due to nonresponse	N/A
14	M	43	3	24	24	No	No	100	Completed	SVR

^*Excludes cannabis. ETR End of treatment response; EVR Early virological response; F Female; M Male; N/A Not applicable; SVR Sustained virological response; tox Toxicology